Ajax Therapeutics Expands Management Team to Support Advancement of New Therapies for Hematologic Malignancies
Christina Riordan, Ph.D., appointed Vice President of Preclinical Development
Craig Masse, Ph.D., promoted to Senior Vice President of Discovery Research
NEW YORK, September 29, 2021– (BUSINESS WIRE) – Ajax Therapeutics, Inc., a biotechnology company applying computational chemistry and structure-based technologies to develop new small molecules for hematologic malignancies, today announced that the company has expanded its leadership team with the appointment of Christina Riordan, Ph.D., as vice president of preclinical development and advancement of Craig Masse, Ph.D., as senior vice president of discovery research .
“We are delighted to welcome Christina to the Ajax team. With extensive experience in all aspects of non-clinical development, from discovery to INDs as well as NDA preparation, Christina will be instrumental in guiding Ajax’s ongoing discovery programs to the clinic. , “said Martin Vogelbaum, interim CEO of Ajax.
“Craig has successfully built and managed Ajax’s distributed research organization, including the company’s collaboration with Schrödinger, since the inception of the company and we look forward to his continued leadership as Senior Vice President of discovery research, ”added Mr. Vogelbaum. Dr Craig Masse joined Ajax in 2019 and previously held senior R&D positions at Nimbus, Concert Pharmaceuticals and Amgen. He is the inventor of more than 60 patents and is co-author of more than 65 scientific publications, including several book chapters. Dr Masse obtained his doctorate. in Synthetic Organic Chemistry from Boston University and conducted post-doctoral research at Harvard University.
Dr Christina Riordan joins Ajax after working at Certara, Inc., where she was Senior Director of Integrated Drug Development for Certara Strategic Consulting and responsible for non-clinical activities including toxicology and safety pharmacology. Dr. Riordan also served as Senior Director, Non-Clinical Safety for Surface Oncology, where she developed and led the overall safety pharmacology and toxicology strategy for all research and development programs. Previously, Dr Riordan held various positions in small and large biotechnology companies, guiding drug development programs across many INDs and further into the clinic. She started her career as a senior researcher at Roche Palo Alto and Hoffman La Roche. Dr. Riordan received her doctorate. in Molecular Genetics / Immunology and Infectious Diseases from the State University of New York at Albany.
About Ajax Therapeutics
Ajax Therapeutics, Inc. pursues unique, selective approaches to develop novel therapies targeting the major cytokine signaling pathways that lead to hematologic malignancies. By combining the in-depth cancer and structural biology knowledge of our founding scientists with the industry’s most advanced computer drug and protein structure discovery platforms from our founding partner, Schrödinger, Inc., we aim to discover and to develop therapies designed more specifically to address important unmet needs. for patients with hematologic malignancies. Please find more information at www.ajaxtherapeutics.com.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20210929005015/en/
Kathryn Morris, The Yates Network